The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Innsbruck Medical University - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Innsbruck Medical University human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Innsbruck Medical University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Innsbruck Medical University’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Innsbruck Medical University’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Innsbruck Medical University in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Innsbruck Medical University’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Innsbruck Medical University.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Innsbruck Medical University and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Innsbruck Medical University Snapshot 5
Innsbruck Medical University Overview 5
Key Information 5
Key Facts 5
Innsbruck Medical University - Research and Development Overview 6
Key Therapeutic Areas 6
Innsbruck Medical University - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Innsbruck Medical University - Pipeline Products Glance 12
Innsbruck Medical University - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Innsbruck Medical University Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Innsbruck Medical University-Early Stage Pipeline Products 14
Discovery Products/Combination Treatment Modalities 14
Innsbruck Medical University - Drug Profiles 15
ATG + Tacrolimus + Tacrolimus + MMF therapy 15
Product Description 15
Mechanism of Action 15
RandD Progress 16
Campath-1H + Tacrolimus 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Pressyn 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Bevacizumab + Irinotecan 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Doxorubicin + Gemcitabine 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Panitumumab + Cisplatin + Radiation Therapy 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Sunitinib 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
SOCS-1 protein 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Innsbruck Medical University - Pipeline Analysis 24
Innsbruck Medical University - Pipeline Products by Therapeutic Class 24
Innsbruck Medical University Pipeline Products By Target 27
Innsbruck Medical University - Pipeline Products by Route of Administration 29
Innsbruck Medical University - Pipeline Products by Molecule Type 30
Innsbruck Medical University - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 33
Contact Us 33
Disclaimer 33List of Tables
Innsbruck Medical University - Pipeline by Therapy Area and Indication, 2010 8
Innsbruck Medical University - Pipeline by Stage of Development, 2010 9
Innsbruck Medical University - Monotherapy Products in Pipeline, 2010 10
Innsbruck Medical University - Combination Treatment Modalities in Pipeline, 2010 11
Innsbruck Medical University - Phase III, 2010 12
Innsbruck Medical University - Phase II, 2010 13
Innsbruck Medical University - Pipeline By Therapeutic Class, 2010 25
Innsbruck Medical University - Pipeline By Target, 2010 28
Innsbruck Medical University - Pipeline By Route of Administration, 2010 29
Innsbruck Medical University - Pipeline By Molecule Type, 2010 30

List of Figures
Innsbruck Medical University - Pipeline by Therapy Area and Indication, 2010 7
Innsbruck Medical University - Pipeline by Stage of Development, 2010 9
Innsbruck Medical University - Monotherapy Products in Pipeline, 2010 10
Innsbruck Medical University - Combination Treatment Modalities in Pipeline, 2010 11
Innsbruck Medical University - Pipeline By Therapeutic Class, 2010 24
Innsbruck Medical University - Pipeline By Target, 2010 27
Innsbruck Medical University - Pipeline By Route of Administration, 2010 29
Innsbruck Medical University - Pipeline By Molecule Type, 2010 30

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.